Q2 2026 saw strong core sales and profit growth, led by Specialty Medicines and Vaccines, while total profit and EPS declined due to significant impairments. Guidance for 2026 is reaffirmed, with robust R&D acceleration, major restructuring, and continued shareholder returns through dividends and buybacks.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.